BDRX
NASDAQBiodexa Pharmaceuticals plc American Depositary Shs
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks60-17%
2026-04-192026-10-11
Mix4190d
- SEC Filings33(80%)
- Other6(15%)
- Offering1(2%)
- Market1(2%)
Latest news
25 items- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRBiodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAPOctober 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and database lock Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), NCT06950385. The trial, branded "Serenta" is recruiting at 29 clinical sites across the US and five countries in Europe with a furt
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form EFFECT filed by Biodexa Pharmaceuticals plc American Depositary ShsEFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form F-1 filed by Biodexa Pharmaceuticals plc American Depositary ShsF-1 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- NEWSThe Longview: Fireside Chat with Biodexa CEO Stephen StampToday's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which the only current remedy is surgical removal of the colon and/or rectum.Key takeaways: eRapa is an oral drug candidate designed to reduce or eliminate the need for surgical treatments; a Phase 3 registrational trial, running at 29 U.S. and EU centers, is more than 50 percent enrolled; an interim futility analysis is expected in Q1 2027; FDA and EMA Orphan Drug designations are complemented by $20 million in grant funding from Texas-based CPRIT. CARDIFF, UK / ACCESS News
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,204,218 American Depositary Shares ("ADSs") of the Company (the "Existing Warrants") at an exercise price of $1.05 for gross cash proceeds of approximately $2.3 million, before deducting financial adv
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
BDRX FAQ
5 questionsWhere does BDRX stock trade?
Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is listed on NASDAQ.What sector and industry is BDRX in?
Biodexa Pharmaceuticals plc American Depositary Shs operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BDRX?
Biodexa Pharmaceuticals plc American Depositary Shs has had 1 recent analyst action on file. The most recent action was from Ladenburg Thalmann: Buy with a $800.00 price target on 2024-02-08. Recent price targets cluster around $800.00.What companies are similar to BDRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BDRX side-by-side with any of them on Quantisnow.How can I track BDRX on Quantisnow?
Quantisnow aggregates Biodexa Pharmaceuticals plc American Depositary Shs's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BDRX to receive live email and push alerts on every new disclosure.